Case Study: Regeneron Pharmaceuticals predicts COVID-19 treatment impact with Certara's agent-based modeling

Agent-Based Model Predicts Impact of Monoclonal Antibody Treatment, Prophylaxis & Vaccines on Viral Transmission during Pandemic

Regeneron Pharmaceuticals sought to understand how to prioritize its finite supply of monoclonal antibody treatment to maximize its effectiveness in reducing SARS-CoV-2 viral transmission and improving healthcare outcomes during the COVID-19 pandemic. They partnered with Certara and utilized its Market Access Services to address this complex challenge.

Certara developed an agent-based model to simulate the impact of combining monoclonal antibody treatment, prophylaxis, and vaccines on viral spread. This model helped estimate how different treatment strategies would affect infection and hospitalization rates, guiding critical resource allocation and patient management decisions for Regeneron Pharmaceuticals and informing public health policy for future pandemic preparedness.

Regeneron Pharmaceuticals